A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization.

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.41 which represents a slight increase of $0.07 or 5.22% from the prior close of $1.34. The stock opened at $1.37 and touched ...

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation ...

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Editas Medicine (EDIT – Research Report) today. The company’s shares closed yesterday ...

Editas Medicine Inc (EDIT) stock saw a modest uptick, ending the day at $1.22 which represents a slight increase of $0.08 or 7.02% from the prior close of $1.14. The stock opened at $1.2 and touched a ...

Editas Medicine reports preclinical success in gene editing for sickle cell disease and beta thalassemia, with strategic milestones for 2025. Editas Medicine, Inc. announced significant ...